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Abstract
Chronic pain patients who misuse prescription opioids may suffer from allostatic dysregulation of 
natural reward processing. Hence, this study examined whether prescription opioid misusers with 
chronic pain (n = 72) evidenced decreased natural reward responsiveness relative to non-misusers 
with chronic pain (n = 26). Subjects completed a dot probe task containing pain-related, opioid-
related, and natural reward stimuli while attentional bias (AB) scores and heart rate variability 
(HRV) responses were assessed. Compared to non-misusers, misusers evidenced significantly 
more attenuated HRV responses to opioid, pain, and natural reward cues presented during the dot 
probe task. These significant between-groups differences in HRV were largest during attention to 
natural reward cues, but became non-significant in a sensitivity analysis controlling for opioid 
dosing. In addition, non-misusers evidenced an AB toward natural reward cues, whereas misusers 
did not. Findings suggest that opioid misusers exhibit attentional and autonomic deficits during 
reward processing.
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Chronic exposure to prescription opioid analgesics may result in opioid misuse and 
addiction due to the pharmacologic actions of opioids on the mesocorticolimbic dopamine 
system – the common neural circuitry underlying a broad range of addictive behaviors 
(Koob & Volkow, 2009). Chronic pain patients prescribed long-term opioid analgesic 
pharmacotherapy are at risk for developing prescription opioid use disorder; approximately 
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10% of such individuals exhibit opioid misuse behaviors such as unauthorized dose 
escalation or self-medication of negative affect with opioids (Fishbain, Cole, Lewis, 
Rosomoff, & Rosomoff, 2007). A recent survey of treatment-seeking opioid dependent 
persons found rates of opioid self-medication of negative affective states as high as 90% 
(Garland, Hanley, Thomas, Knoll, & Ferraro, in press). Thus, prescription opioid misusers 
may seek and consume opioids as a means of regulating dysphoria and maintaining a 
positive hedonic tone.
Maintenance of hedonic homeostasis may be undermined by increasing tolerance to the 
effects of opioids coupled with recurrent episodes of chronic pain and coincident negative 
emotions. The individual may thereby be impelled to use increasingly higher doses of 
opioids to allay emotional and somatic distress (Shurman, Koob, & Gutstein, 2010). 
However, this attempt to achieve an equilibrium is costly: chronic opioid use may shift the 
hedonic set point, rendering the individual increasingly insensitive to rewards in the natural 
environment and tipping the hedonic balance further toward negative affectivity (Koob & Le 
Moal, 2008). In turn, the effort to preserve dwindling hedonic tone may fuel a cycle of 
escalating dependence on opioids (Garland, Froeliger, Zeidan, Partin, & Howard, 2013a).
Pre-clinical and clinical studies suggest that addiction to a wide range of substances is 
undergirded by changes in dopaminergically-mediated reward function (Augustus Diggs, 
Froeliger, Carlson, & Gilbert, 2013; Gipson et al., 2013; Heinz et al., 2004; Kalivas & 
Volkow, 2005; Lintas et al., 2012) including attenuated neurobehavioral reactivity to natural 
rewards and heightened reactivity to drug-related cues (Koob & Volkow, 2009; Volkow, 
Wang, Fowler, Tomasi, & Telang, 2011). In contradistinction to healthy, non-addicted 
individuals who exhibit an attentional bias (AB) toward images representing positive, 
naturally rewarding stimuli (Wadlinger & Isaacowitz, 2010), opiate dependent individuals 
evidence an AB to opiate-related visual cues presented for 500 ms on dot probe tasks, as 
evidenced by faster responses to probes replacing opiate photographs than to probes 
replacing neutral probes (Lubman, Peters, Mogg, Bradley, & Deakin, 2000). Similarly, 
prescription opioid dependent chronic pain patients exhibit an AB to prescription opioid 
cues presented for 200 ms (Garland, Froeliger, Passik, & Howard, 2013b). AB for a cue 
presented for ≤ 200 ms is believed to index biases in initial attentional orienting, whereas 
AB for longer duration stimuli (> 500 ms) is believed to index delayed disengagement of 
attention from an emotionally salient cue (Field & Cox, 2008). Moreover, opiate dependent 
individuals exhibit enhanced event-related brain potentials (e.g., P300) to opiate cues 
coupled with attenuated electrophysiological brain responses to images depicting natural 
rewards (Lubman, Allen, Peters, & Deakin, 2007, 2008). Such decreased responsiveness to 
natural rewards is a robust predictor of future opiate use (Lubman et al., 2009). Although the 
studies by Lubman and colleagues support the presence of decreased responsiveness to 
natural rewards among individuals addicted to illicit opiates (e.g., heroin), to our knowledge 
no study has identified reward dysfunction among chronic pain patients who misuse 
prescription opioids. If research demonstrates the presence of deficits in natural reward 
processing among such patients, such a finding would provide a potentially crucial treatment 
target and help to further elucidate the risk chain leading from chronic pain to opioid misuse 
and addiction (for a review, see Garland et al., 2013a).
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Attentional and emotional processing of rewarding or emotionally-salient cues is thought to 
elicit reactivity in a network of central (e.g., prefrontal cortex [PFC], anterior cingulate 
cortex [ACC]) and autonomic nervous system structures with downstream effects on 
visceral and peripheral parameters, including the beat-to-beat modulation of heart rate by the 
vagus nerve, known as high-frequency heart rate variability (HRV) (Thayer & Lane, 2000, 
2009). HRV is mediated by parasympathetic influences on the sinoatrial node of the heart 
(Berntson et al., 1997). Elevated HRV may reflect self-regulatory effort or efficacy 
(Segerstrom & Nes, 2007), and individuals with impairments in regulation of attention, 
emotion, and appetitive urges exhibit attenuated HRV at rest (Ingjaldsson, Laberg, & 
Thayer, 2003a; Thayer & Lane, 2009) and when attempting to suppress craving in response 
to addiction-related cues (Garland, Carter, Ropes, & Howard, 2012). Yet, increased HRV 
can also be elicited as a classically conditioned response to conditioned appetitive stimuli 
(Inagaki, Kuwahara, & Tsubone, 2005; Stockhorst, Huenig, Ziegler, & Scherbaum, 2011). 
Studies have identified cue-elicited increases in HRV associated with craving for addictive 
substances such as methamphetamines, nicotine, and alcohol (Culbertson et al., 2010; 
Erblich, Bovbjerg, & Sloan, 2011; Garland, Franken, Sheetz, & Howard, 2012; Garland, 
Franken, & Howard, 2012; Ingjaldsson, Laberg, & Thayer, 2003; Rajan, Murthy, 
Ramakrishnan, Gangadhar, & Janakiramaiah, 1998), and increased HRV during exposure to 
food cues (Udo et al., 2013) which abates upon consumption of a meal (Nederkoorn, 
Smulders, & Jansen, 2000). Thus, HRV may be a useful index of self-regulation and reward 
responsiveness among prescription opioid misusing chronic pain patients, though no study 
has examined this measure in this clinical population to date.
To address the dearth of findings in this potentially important research area, the present 
study aimed a) to establish whether prescription opioid misusers with chronic pain evidence 
decreased natural reward responsiveness (as indicated by HRV responses) relative to chronic 
pain patients who take opioids as medically prescribed and b) to determine whether 
prescription opioid misusers with chronic pain exhibit comparatively attenuated cardiac-
autonomic control during attention to a range of emotionally-salient cues. As converging 
evidence of reward dysregulation, we sought to determine if opioid misuse was associated 
with reduced AB to natural reward cues.
To examine these questions in the present study, a sample of opioid-misusing chronic pain 
patients (opioid misusers) and chronic pain patients who did not misuse opioids (non-
misusers) completed a dot probe task in which opioid-related, pain-related, and natural-
reward images were presented while HRV was measured concurrently. We had three 
hypotheses: 1) as an index of impaired cardiac-autonomic control during regulation of 
attention to emotional information, opioid misusers would exhibit significantly less phasic 
cue-elicited HRV during the dot probe task than non-misusers, but would not show 
differences in resting state HRV at baseline; 2) given that deficits in natural reward 
processing are a hallmark of addiction, these phasic HRV differences would be most 
pronounced for natural reward-related cues; and 3) as further evidence of deficient reward 
processing, we also hypothesized that the non-misuser group would exhibit a significant 
positive AB towards natural reward cues, whereas the opioid misuser group would not 
exhibit this normative positive AB - indicative of their underlying reward deficit.
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Participants met eligibility criteria if they had a diagnosable chronic pain condition, had 
been prescribed long-term analgesic pharmacotherapy (for at least 90 days, see clinical 
guidelines presented in Chou et al., 2009), and had taken opioids daily or nearly every day 
(≥ 5 days/week) for >3 months. Participants were recruited from primary care clinics, pain 
clinics, and neurology clinics in Tallahassee, FL via flyers and online classified ads. 
Advertisements sought to recruit participants who “suffer from and are prescribed medicine 
for chronic pain” for a study focused on improving ways to address problems with chronic 
pain and prescription pain medication. Prescription opioid misuse was determined by scores 
on the self-reported Current Opioid Misuse Measure (COMM; α = .83) (Butler et al., 2007). 
The original COMM validation study conducted with patients treated in specialty pain 
management clinics found that a score of ≥9 was suggestive of prescription opioid misuse. 
However, according to a study of a broad sample of chronic pain patients from a variety of 
primary care settings who took prescription opioids but not necessarily on a daily basis, 
receiver–operator characteristic curve analyses revealed that a score of 13 or higher on the 
COMM had maximum sensitivity and specificity to identify prescription opioid misuse 
among chronic pain patients in primary care settings (Meltzer et al., 2011). We chose this 
more conservative COMM threshold value to minimize false positives and because, similar 
to Meltzer et al. (2011), our sample was broad and not confined to patients from specialty 
pain clinics.
Based on this cutoff score, participants were grouped into one of two groups: a group of 
chronic pain patients who took prescription opioids daily/nearly every day and reportedly 
engaged in opioid misuse behaviors (misusers, n = 72), and a group of chronic pain patients 
who took prescription opioids daily/nearly every day without engaging in opioid misuse 
(non-misusers, n = 26). Table 1 describes participant demographics and prevalence of 
various chronic pain conditions in the sample.
Data Collection
Current opioid misuse measure—The Current Opioid Misuse Measure (COMM; α =.
83) (Butler et al., 2007) assessed self-reported aberrant drug-related behavior. Participants 
responded to 17 items rated on a Likert scale (0 = never, 4 = very often) regarding how often 
in the past 30 days they had engaged in behaviors potentially reflective of opioid misuse or 
took opioid medication in excessive doses or in nonprescribed ways, tapped by items such as 
“In the past 30 days, how often have you taken your medications differently from how they 
are prescribed?”, “In the past 30 days, how often have you used your pain medicine for 
symptoms other than for pain (e.g., to help you sleep, improve your mood, or relieve 
stress)?”
Dot probe task—A dot probe task was used to measure AB to opioid-related, pain-related, 
and natural reward cues. Each trial began with a fixation cross (i.e., crosshair) presented for 
500 ms. Next, two images matched for visual complexity, composition, and figure-ground 
relationships appeared side by side on the computer screen for either 200 or 2000ms. Pairs 
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of photos containing one emotionally-salient image and one neutral image were presented. 
Three blocks of cues (opioid-related, pain-related, and pleasure-related) were presented in 
randomized, counterbalanced order across participants. Specific picture cues were presented 
in a randomized order within each block and blocks were counterbalanced across 
participants.
Three sets of 12 photographs, each set representing one type of cue, were selected from the 
International Affective Picture System (IAPS) (Lang, Bradley, & Cuthbert, 1997) and media 
libraries on the Internet. Opioid-related cues included images of pills and pill bottles. Pain-
related cues included images of severe injuries, painful medical procedures, and human 
faces grimacing in pain. Natural reward cues included images of romantic couples, athletic 
victories, and food. A set of 36 neutral images was selected from the IAPS and each neutral 
image was paired with an emotionally-salient image matched for visual features such as 
color, figure-ground relationships, and presence of human faces.
Presentation duration and left/right position of the images were randomized and 
counterbalanced within each block of 64 trials. Half (n = 32) of the trials for each cue type 
were presented in each visual field (VF: left VF, right VF), and within each VF, half of the 
trials were presented at each presentation duration (200 ms, n = 16; 2000 ms, n = 16). The 
image pairs disappeared, and a target probe replaced one of the images after a 50 ms inter-
stimulus interval (ISI). Probes appeared for 100 ms, and probe location (left VF, right VF) 
was counterbalanced. Each block was presented 1 time, and the order of blocks over the 
timecourse of the task was counterbalanced across participants. Participants indicated the 
location of the target by responding with a left/right button press, and the reaction time (RT) 
was recorded.
HRV Measurement—Disposable Ag-AgC1 electrodes were attached to participants' right 
and left pectoral muscles. Electrocardiogram (ECG) data were sampled at 1000 Hz and 
recorded continuously throughout the protocol on a Biopac MP150 (Biopac Systems, 
Goleta, CA). Respiration rate was concomitantly assessed with a breathing belt and also 
recorded on the Biopac MP 150 system.
Procedures
Participants were instructed to take their prescribed opioid medication as usual on the day 
they completed study measures. In a single session, participants first completed the Current 
Opioid Misuse Measure, and next were instructed to remain motionless and silent for a 5-
minute baseline, after which they participated in the dot probe task (which took 
approximately 15 minutes to complete). All participants provided written, informed consent 
and were compensated $25 for their participation in the study. The study was approved by 
the Human Subjects Committee of Florida State University and comports with ethical 
provisions set in the Declaration of Helsinki.
Data Reduction
Regarding the analysis of AB data for each participant, trials with extreme RTs, defined as 
those with RTs 3 SD above or below the individual mean RT (Field, Mogg, Zetteler, & 
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Bradley, 2004; Ratcliffe, 1993), were eliminated as outliers (< 2% of trials were discarded). 
Trials on which the probe location was incorrectly identified were also omitted in AB 
analyses (misusers 15.3% ± 1.7%; non-misusers 9.9% ± 2.9%) – there was no significant 
between-groups difference in accuracy on the task. Opioid, pain, and natural reward AB 
scores were calculated by subtracting participants' mean RT to target probes replacing 
emotionally salient photos (opioid, pain, or natural reward cues) from their mean RT to 
target probes replacing neutral photos, such that positive bias scores indicate an AB toward 
emotionally salient cues. One-sample Kolmogorov-Smirnov tests revealed that the 
distributions of the 200ms AB scores and 2000 ms AB scores did not significantly differ 
from a normal distribution.
With respect to the HRV analyses, R-R intervals were detected in the ECG data using 
automated routines in Acqknowledge 4.1 software (BIOPAC, Inc.). The R-wave file was 
then visually inspected to correct misidentified or omitted R-waves. Kubios 2.0 (Biosignal 
Analysis and Medical Imaging Group, University of Finland) was used to calculate beats-
per-minute (BPM) and for spectral analysis of R-waves. R-R interval data was segmented 
into the following windows: the 5-minute baseline, the opioid cue block, the pain cue block, 
and the natural reward cue block. A fast Fourier transform was applied separately to R-R 
interval data in each time window to extract normalized high-frequency HRV from a de-
trended, end-tapered interbeat interval time series. We used standard default spectrum 
estimation settings in Kubios prior to applying the Fourier transform (window width: 256s, 
window overlap: 50%). High-frequency HRV in the respiratory frequency band (0.15 – 0.40 
Hz) was selected as our estimate of vagally-mediated HRV. Heart rate variability frequency 
measures can allow for disentanglement of predominately parasympathetically-mediated 
HRV (i.e., high-frequency HRV) from HRV driven by parasympathetic and sympathetic 
influences (i.e., low-frequency HRV) (Berntson, 1997; Malliani, Lombardi, Pagani, 1994). 
Following Berntson (1997) and Malliani et al. (1994), we calculated high-frequency in 
normalized units to elucidate shifts in this frequency component that might otherwise be 
obscured by use of absolute units which are dependent on total HRV power (including very 
low frequency HRV). HRV was averaged for each of the dot probe cue blocks separately, 
and was also averaged across the 5-minute baseline. Because there was no significant Group 
(F(1,84) = 1.14, p = .29) or Group × Condition difference (F(1,84) = .19, p = .95) in 
respiration rate between misusers and non-misusers, we did not control for respiration rate in 
our HRV analyses. HRV data were skewed and log-transformed for subsequent analyses.
Statistical Analysis
For hypothesis testing, we used the following multistage analytic approach. To test 
hypothesis 1, we first conducted a One-Way ANOVA to examine differences in resting state 
HRV between misusers and non-misusers. Next, we conducted a two-way Repeated 
Measures-ANOVA (RM-ANOVA) on the phasic HRV data with Group (misusers, 
nonmisusers) and Condition (baseline, opioid cue block, pain cue block, pleasure cue block) 
as factors. In this ANOVA, the main effect of Condition tested to what extent HRV differed 
between each of the dot probe cue blocks and from resting baseline levels (this was followed 
by planned contrasts to further specify this effect), whereas the Group × Condition 
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interaction term tested whether misusers and non-misusers significantly differed on HRV 
values at rest and during each of the dot probe cue conditions.
To test hypothesis 2 and assess between-groups differences in phasic, cue-elicited HRV 
responses, planned contrasts (contrasting HRV during each of the cue conditions with 
baseline HRV as the reference category) were used to determine whether opioid misusers 
and nonmisusers significantly differed with regard to HRV increases from resting baseline 
levels to each of the dot probe cue conditions (with a specific focus on HRV responsivity to 
natural reward cues). This computation mathematically produces the same results as using a 
difference score. In sensitivity analyses, we conducted a RM-ANOVA on phasic HRV 
scores, controlling for potentially confounding variables with known or theoretical effects 
on HRV, including age, gender, number of years experiencing chronic pain, and morphine 
equivalent daily opioid dose.
To test hypothesis 3, we conducted one sample t-tests to identify the presence of 
significantly nonzero AB scores for natural reward cues among misusers and non-misusers. 
Supplementary t-tests tested for the presence of significantly nonzero AB scores for opioid 
and pain-related cues among misusers and non-misusers. A follow-up ANCOVA using the 
covariates listed above was used to test between-groups differences in AB.
Results
Resting-State HRV and Phasic HRV Cue Responses—With regard to hypothesis 1, 
there was no significant difference in basal, resting-state HRV between the misuser and non-
misuser groups, F(1,97) =.004, p = .95. With regard to phasic HRV cue responses, the main 
effect of Condition was significant, F(3,96) = 4.74, p = .003, η2partial = .05, indicating that 
HRV differed from baseline to the various cue blocks on the dot probe task. Planned 
contrasts indicated that this effect was largely driven by significantly increased phasic HRV 
from baseline to opioid cue exposure across both groups, F(1,96) = 11.62, p = .001, η2partial 
=.11, though HRV also increased significantly to pain (F(1,96) = 4.46, p = .037, η2partial = .
04) and pleasure cues (F(1,96) = 4.64, p = .034, η2partial = .05). The main effect of Group 
was marginally significant, (F(1,96) = 3.84, p = .05, η2partial = .04), indicating that opioid 
misusers evidenced less HRV averaged across all conditions of the protocol than non-
misusers. Crucially, the omnibus Group × Condition interaction was significant, F(3,96) = 
3.51, p = .02, η2partial = .04. With regard to hypothesis 2, to clarify this significant 
interaction, planned contrasts revealed that HRV increased to a significantly greater extent 
for non-misusers than for misusers from resting baseline to the opioid cue block, F(1,96) = 
5.19, p = .03, η2partial = .05, the pain cue block, F(1,96) = 5.23, p = .03, η2partial = .05, and 
the pleasure cue block, F(1,96) = 6.33, p = .01, η2partial = 06. These between-groups 
differences were most pronounced for pleasure cues (see Figure 1).
Sensitivity analysis—In a sensitivity analysis, a RM-ANOVA controlling for age, 
gender, duration of chronic pain, and morphine equivalent daily opioid dosage indicated that 
the main effect of Condition was non-significant, F(3,31) = 1.88, p = .14, η2partial = .06, as 
was the main effect of Group, F(3,31) = 1.68, p = .20, η2partial = .05. However, the omnibus 
Group × Condition interaction was significant, F(3,31) =3.09, p = .03, η2partial = .09. To 
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clarify this significant interaction, planned contrasts indicated that the non-misuser group 
experienced significantly greater increases in HRV to pain cues compared to the misuser 
group (F(1,31) = 7.06, p = .01, η2partial =.19), but did not differ significantly with regard to 
HRV response to opioid (F(1,31) = 3.52, p = .07, η2partial =.10) or natural reward cues 
(F(1,31) = 2.38, p = .13, η2partial = .07).
AB Scores—With regard to hypothesis 3, among the non-misuser group, we observed a 
significantly nonzero AB toward natural reward cues presented for 200 ms (M = 11.02 ± 
4.52 ms; one-sample t-test, t = 2.43, p = .02). Among the misuser group, we observed a 
nonsignificant AB away from natural reward cues presented for 200 ms (M = -6.46 ± 6.83 
ms; one-sample t-test, t = .35, p > .10). Supplementary analyses revealed that both non-
misusers (M = 15.39 ± 6.74 ms; one-sample t-test, t = 2.28, p = .03) and misusers had a 
significant AB toward prescription opioid cues presented for 200 ms (M= 18.18 ± 4.42 ms; 
one-sample t-test, t = 4.11, p < .001). In contrast, AB scores for reward and opioid cues 
presented for 2000 ms did not significantly differ from zero, suggesting that AB was only 
present during initial attentional orienting and not during sustained attention (Field & Cox, 
2008). In addition, neither non-misusers nor misusers evidenced a significant AB toward 
pain-related cues at either stimulus duration. A sensitivity analysis controlling for gender, 
age, duration of pain, and opioid dose revealed no significant between-groups effects on AB 
scores for any cue type or stimulus duration. AB scores were not significantly associated 
with resting state HRV or phasic cue-elicited HRV responses.
Discussion
In this study of chronic pain patients taking prescription opioid analgesics for at least 90-
days, opioid misusers had significantly more attenuated HRV responses during attention to 
emotional information than individuals with at low risk for opioid misuse. Indeed, while 
non-misusers exhibited an increase in HRV from baseline across all three emotional cue 
types, opioid misusers evidenced comparatively blunted phasic HRV cue responses. This 
differential autonomic response was most pronounced for natural reward cues. Congruent 
with this finding, the non-misuser group exhibited a 200 ms AB to natural reward cues, 
whereas the misuser group had no such AB. Importantly, there were no significant between-
groups differences in tonic, resting-state HRV. This finding suggests that the 
neuropharmacologic effects of opioids may not impact tonic, resting-state HRV but may 
instead inhibit HRV cue responsiveness. Alternatively, this finding may suggest that 
observed differences in HRV cue responsiveness may have stemmed from the effects of 
addictive processes on dysregulation of central-autonomic responses.
Across both groups of opioid-using patients, HRV increased significantly from resting-state 
levels during opioid cue trials. Such increases in HRV cue responses have been observed in 
preclinical models of appetitive conditioning which indicate that heightened HRV elicited 
by conditioned stimuli is associated with a reward expecting state (Inagaki et al., 2005), and 
clinical studies of persons experiencing appetitive responses to addictive drugs (Culbertson 
et al., 2010; Erblich et al., 2011; Rajan et al., 1998) as well as food cues (Udo et al., 2013). 
Moreover, increases in alcohol cue-elicited HRV predicted the time-course of relapse among 
alcohol dependent individuals up to six months following treatment (Garland et al., 2012). 
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Thus, phasic HRV elicited by opioid cues may reflect appetitive responding and/or 
conditioned reward. Supporting this interpretation, both groups of patients exhibited an AB 
towards opioid cues presented for 200 ms. The 200 ms AB is commonly held to index bias 
in initial attentional orienting (Field & Cox, 2008). As in the HRV responses to opioid cues, 
both groups of patients exhibited heightened HRV responses to pain cues, possibly 
indicating attentional processing of emotionally salient stimuli.
Importantly, non-misusers experienced significantly greater autonomic (i.e., HRV) and 
attentional (i.e, AB) responses to natural reward cues relative to opioid misusers. To our 
knowledge, this is the first finding in the literature that chronic pain patients who misuse 
prescription opioids exhibit pronounced reward processing deficits relative to chronic pain 
patients who take opioids as prescribed. Prior preclinical studies have demonstrated effects 
of chronic pain on brain reward systems which parallel the clinical observation that chronic 
pain is often accompanied by significant anhedonia and loss of motivation to obtain reward 
(Becker, Gandhi, & Schweinhardt, 2012; Schwartz et al., 2014). Yet, the present study 
suggests that prescription opioid misuse is associated with additional reward deficits above 
and beyond the presence of chronic pain. Putatively, such reward deficits drive escalation of 
opioid misuse as a means of coping with dysphoria stemming from chronic pain and 
mesocorticolimbic dopamine system dysregulation (Garland et al., 2013a). That is, study 
findings provide support for the allostatic model of addiction (Koob & Le Moal, 2001, 
2008). The allostatic model posits that prolonged exposure to drug experiences results in an 
upward shift in basal reward threshold, leading to a reward deficit and dysphoric mood that 
encourages increased consumption of drugs as a means of achieving an overall positive 
affective balance. Ironically, this attempt to reach a positive affective state comes with a 
cost: the continued use of drugs further increases brain reward thresholds, making the 
individual increasingly insensitive to naturally-rewarding experiences while becoming 
increasingly sensitive to stress and pain (Koob & Le Moal, 2001). Although prior studies 
have identified allostatic dysregulation of reward processing among opiate addicts, the 
present study provides novel evidence that such allostatic processes may also undergird 
prescription opioid misuse among chronic pain patients.
It is possible that the reduced reward responsiveness observed among the opioid-misusing 
patients in this study was a product of the allostatic state induced by chronic high dose 
opioid exposure; this interpretation is bolstered by the finding that after controlling for 
differences in opioid dosing, there were no significant between-groups differences in HRV 
or AB responses to natural reward and opioid cues. However, we cannot rule out that age, 
gender, or chronic pain duration might also be responsible for these effects, given that these 
variables were also controlled in our sensitivity analyses. Indeed, age and gender are known 
to influence HRV (Antelmi, De Paula, Shinzato, Peres, Mansur, & Grupi, 2004) and AB 
towards positive affective stimuli (Wadlinger & Isaacowitz, 2010). Moreover, AB and HRV 
have been linked with chronicity of pain (Schoth, Nunes, & Liossi, 2012; Nes, Roach, & 
Segerstrom, 2009) and severity of drug use and/or addiction severity (Field & Cox, 2008; 
Garland, Franken, & Howard, 2012). Given that these factors are known to be associated 
with attentional and autonomic regulation, it is perhaps unsurprising that the observed 
between-groups effects on cue-elicited HRV and AB responses did not survive statistical 
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correction for duration of chronic pain, drug use severity, gender, and age – by using this set 
of covariates, we were in effect controlling for factors linked with the outcome of interest.
Importantly, the observed between-groups difference in phasic HRV response to pain-
related cues remained significant even after controlling for these factors, suggesting that 
regardless of chronicity of pain or opioid dosage (as well as age and gender), opioid 
misusing chronic pain patients exhibit comparatively attenuated parasympathetic response to 
emotionally threatening stimuli. While cue-elicited increases in HRV to appetitive stimuli 
are thought to index reward responsiveness (Inagaki et al., 2005), cue-elicited increases in 
HRV to emotionally aversive stimuli are thought to index self-regulation (Segerstrom & 
Nes, 2006) or emotion regulation (Thayer & Lane, 2000; 2009). Indeed, reduced cue-elicited 
HRV during emotion regulation has been observed among persons with high neuroticism 
relative to those with low neuroticism (Di Simplicio, Costoloni, Western, Hanson, Taggart, 
& Harmer, 2012). In this light, our findings may imply the presence of self-regulatory 
deficits among opioid misusing chronic pain patients (Nes et al., 2009), at least with respect 
to autonomic regulation of homeostatic perturbations elicited by pain-related stimuli. 
Hypothetically, deficient regulation of negative emotional responses might promote opioid 
misuse among chronic pain patients by exacerbating craving and maladaptive cognitive 
processes (Garland et al., 2013a; Martel, Dolman, Edwards, Jamison, & Wasan, 2014).
Irrespective of the etiology of the observed neurocognitive deficits among opioid misusers 
in this sample, restructuring reward responsiveness may be a fruitful target for opioid misuse 
interventions, as evidenced by a recent study which found that the therapeutic effects of a 
Mindfulness-Oriented Recovery Enhancement intervention on reducing prescription opioid 
craving were statistically associated with increases in natural reward processing as indicated 
by cardiac-autonomic responses (Garland, Froeliger, & Howard, 2014a) and event-related 
potentials (Garland, Froeliger, & Howard, 2014b).
The primary limitation of this study was the fact that we assessed a sample of volunteers and 
that we confined our primary analyses to those subjects who had no missing data. These 
procedures might have implications for the generalizability of our findings, as patient 
samples who volunteer for research may significantly differ from those who do not. Also, 
we characterized patients as opioid misusers based on their score on a self-report instrument 
(the COMM). Because some patients may be reluctant to admit to opioid misuse on a self-
report measure, reporting bias is possible. Moreover, following Meltzer et al. (2011), we 
selected a more conservative COMM threshold value than the original COMM validation 
study (Butler et al., 2007) to minimize false positives. For these reasons, we may not have 
been able to correctly classify all the misusers in the sample. Nonetheless, participants were 
assured of confidentiality, and the majority endorsed opioid misuse on this measure even 
with the more restrictive threshold. Lastly, we instructed participants to take their opioids as 
prescribed on the day of the dot probe testing session to prevent opioid withdrawal which 
might have had deleterious effects on participants' health and cognitive performance. Yet, 
medication use might have influenced performance on the dot probe task. As such, we 
included morphine equivalent daily dose as a covariate in sensitivity analyses. Although the 
findings should be considered preliminary and heuristically informative, this exploratory 
study helps to raise a number of key issues that should be explored in larger and more well-
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controlled studies which couple neuroimaging with autonomic and pharmacologic probes to 
disentangle the differential contribution to deficient HRV cue responses made by the purely 
pharmacologic effects of acute opioid exposure from the effects of neural dysfunction 
associated with addictive processes.
In conclusion, results from this study suggest that opioid-misusing chronic pain patients 
exhibit attenuated natural reward processing relative to pain patients who take opioids as 
prescribed. This reward processing deficit may stem from the allostatic state induced by 
chronic high dose opioid exposure or from the effects of addiction on dysregulation of 
central-autonomic cue-responses. Regardless of its source, deficient reward processing may 
be an important risk factor for the development and maintenance of prescription opioid 
misuse and addiction.
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• As addiction progresses, natural reward processing becomes dysregulated
• Prescription opioid misusers may exhibit deficits in natural reward processing
• Opioid misusers exhibited reduced HRV while attending to natural reward cues
• Unlike misusers, non-misusers have an attentional bias towards natural reward 
cues
• Reduced reward processing may indicate opioid misuse risk in chronic pain 
patients
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High frequency heart rate variability (HRV) responses in normalized units (n.u.) at resting 
baseline and during each of three blocks of cues on a dot probe task among a sample of 
prescription opioid misusing chronic pain patients (misusers, n = 72) and those at low risk 
for prescription opioid misuse (non-misusers, n = 26). Error bars indicate ± 1 standard error.
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Attentional bias (AB) scores for opioid, pain-related, and natural reward cues presented for 
200 ms during a dot probe task among a sample of prescription opioid misusing chronic pain 
patients (misusers, n = 72) and those at low risk for prescription opioid misuse (non-
misusers, n = 26). Positive scores indicate a bias towards the emotionally-salient cue; 
negative scores indicate a bias away from the emotional cue. Error bars indicate ± 1 standard 
error.
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Table 1





Age (years) 46.6 (SD = 13.4) 47.3 (SD = 11.6)
Gender (women, %) 49 (69.2%) 18 (68.1%)
Chronic pain conditionsa:
 Lumbago 43 (59.7%) 13 (50.0%)
 Fibromyalgia 13 (18.0%) 7 (26.9%)
 Arthritis 5 (6.9%) 2 (7.7%)
 Cervicalgia 5 (6.9%) 0 (0.0%)
 Other 6 (8.3%) 4 (15.3%)
Duration of chronic pain (years) 10.7 (11.0) 12.7 (9.5)
Opioid misuse score (COMM) 21.9 (9.2) 8.5 (3.1)
a
Note: Participants could report more than one chronic pain condition.
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